Intel 471 Releases Report to Help Europe’s Critical Entities Navigate the Network and Information Security Directive (NIS2)
5.11.2024 10:00:00 EET | Business Wire | Press release
Today, Intel 471, a global leader in cyber threat intelligence (CTI) and intelligence-driven solutions, released its new report, NIS2 Operationalising Cyber Threat Intelligence for Critical Infrastructure Resiliency.The report offers key insights into how actionable CTI can help organisations navigate Europe’s new cybersecurity regulations, proactively mitigate digital risk, improve cyber resilience, and avoid penalties and fines.
National laws implementing the European Union’s NIS2 Directive (EU) 2022/2555 to lift the cyber resilience of critical infrastructure across Europe went into effect on 18 October 2024. NIS2 has dramatic implications for how important and essential operators of critical services manage cyber risks compared to its predecessor, NIS1, the 2016 Network and Information Systems Directive. It gives regulators wider supervisory powers, introduces higher standards for cyber risk management, mandatory incident reporting and tougher sanctions. If not followed, essential entities face administrative fines of up to €10 million, or 2% of annual global turnover, whichever is higher. This directive is a major shift in cyber risk management and supply chain security for entities operating energy, transport, banking, health, water, digital infrastructure, managed IT services, public administration and many more subsectors.
In this report, Intel 471 outlines how these entities in critical sectors affected by the European Commission’s NIS2 Directive can leverage premier CTI and intelligence-driven threat hunting to proactively mitigate digital threats and meet the directive’s higher risk management and incident reporting requirements. The report provides organizations with best practices to reduce cyber risk, anticipate threats, prioritise remediation of cloud resources and other IT assets, and continuously improve risk management measures to boost resilience and recovery.
“It is the right time to adopt NIS2 given today’s high stakes cybersecurity threat landscape. We’re seeing nation-state and cybercrime activity increasingly overlap, often driven by geopolitical events that create higher risks to all critical sectors in Europe. Defenders are overwhelmed by data and need timely intelligence that helps them focus on emerging threats, adversary tactics, and vulnerabilities that pose the greatest risk to them,” says Michael DeBolt, Chief Intelligence Officer at Intel 471. “Our unmatched human intelligence capability, patented malware emulation and tracking insights, and human-validated automated collection across thousands of threat actor communities help our customers in critical sectors across the globe understand their exposure and proactively mitigate digital risks. We go a step further by providing carefully curated intelligence-driven threat hunting content to rapidly identify and stop advanced threats in their tracks.”
Organisations impacted by NIS2 can utilise Intel 471’s unique CTI capabilities to improve security posture, reduce their attack surface and enhance resilience. “Being prepared with timely and trusted intelligence and threat hunting content that identifies adversarial techniques missed by traditional detection methods is critical for organisations to gain early visibility of emerging threats and proactively respond to cyber incidents. This intelligence-led approach to cyber defense and third party risk is at the heart of NIS2 directive,” says DeBolt.
NIS2’s broader scope than NIS1 dictates that many affected entities are urgently working to mature their CTI programs to better support their NIS2 cyber risk management strategies. The CTI Capability Maturity Model (CTI-CMM) — a free and vendor-neutral, “stakeholder-first” model, sponsored by Intel 471 and 27 other CTI industry expert peers from across the globe, assists organisations in building successful, impactful CTI programs.
For more details and to download the Intel 471 report, please visit: NIS2 Operationalising Cyber Threat Intelligence for Critical Infrastructure Resilience
About Intel 471
Intel 471 empowers enterprises, government agencies, and other organizations to win the cybersecurity war using the real-time insights about adversaries, their relationships, threat patterns, and imminent attacks relevant to their businesses. The company’s platform collects, interprets, structures, and validates human-led, automation-enhanced intelligence, which fuels our external attack surface and advanced behavioral threat hunting solutions. Customers utilize this operationalized intelligence to drive a proactive response to neutralize threats and mitigate risk. Organizations across the globe leverage Intel 471’s world-class intelligence, our trusted practitioner engagement and enablement, and globally dispersed ground expertise as their frontline guardian against the ever-evolving landscape of cyber threats to fight the adversary — and win. Learn more at www.intel471.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241105566758/en/
Contacts
Erica Stuchel
Intel471@w2comm.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 17:00:00 EEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 16:34:00 EEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 12:00:00 EEST | Press release
Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely with healthcare authorities and other stakeholders to support timely access for people with Parkinson’s disease who continue to experience moderate to severe motor fluctuations despite current oral therapies. Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. Despite availab
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 11:16:00 EEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 11:00:00 EEST | Press release
Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich, the findings show that the clinically relevant reductions in low-density lipoprotein cholesterol (LDL-C) achieved within the first year of treatment are estimated to translate into clinically meaningful reductions in 10-year cardiovascular (CV) risk.1 The data further reinforce the clinical value of bempedoic acid, and its fixed-dose combination with ezetimibe, across a diverse range of patient subtypes, regardless of gender and glycaemic profile (diabetes, pre-diabetes, or normoglycemia).2,3 Key findings from the new analyses of the MILOS study include: 10-year CV risk estimate reduction: An analysis of 960 at-risk patients estimated that one year of bempedoic acid-add-on ther
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom